{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:06:05Z","timestamp":1789049165945,"version":"build-2803163510"},"reference-count":221,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Medical Research Council (NMRC) Open Fund Young Individual Research Grant","award":["MOH-001351"],"award-info":[{"award-number":["MOH-001351"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ncRNA"],"abstract":"<jats:p>Psoriasis, a widespread and chronic inflammatory skin disorder, is marked by its persistence and the lack of a definitive cure. The pathogenesis of psoriasis is increasingly understood, with ongoing research highlighting the intricate interplay of genetic, immunological, and environmental factors. Recent advancements have illuminated the pivotal role of microRNAs in orchestrating complex processes in psoriasis and other hyperproliferative skin diseases. This narrative review highlights the emerging significance of miRNAs as key regulators in psoriasis pathogenesis and examines their potential as therapeutic targets. We discuss current treatment approaches and the promising future of miRNAs as next-generation therapeutic agents for this condition.<\/jats:p>","DOI":"10.3390\/ncrna11010016","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:03:35Z","timestamp":1739419415000},"page":"16","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2398-3862","authenticated-orcid":false,"given":"Li Tian Keane","family":"Teo","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Imperial College London, Sir Ernst Chain Building, South Kensington, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerissa","family":"Juantuah-Kusi","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK"},{"name":"A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology, and Research (A*STAR), 8A Biomedical Grove #06-06 Immunos, Singapore 138648, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-6770","authenticated-orcid":false,"given":"Gowtham","family":"Subramanian","sequence":"additional","affiliation":[{"name":"A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology, and Research (A*STAR), 8A Biomedical Grove #06-06 Immunos, Singapore 138648, Singapore"},{"name":"Skin Research Institute of Singapore (SRIS), 11 Mandalay Road #17-01 Clinical Sciences Building, Singapore 308232, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-498X","authenticated-orcid":false,"given":"Prabha","family":"Sampath","sequence":"additional","affiliation":[{"name":"A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology, and Research (A*STAR), 8A Biomedical Grove #06-06 Immunos, Singapore 138648, Singapore"},{"name":"Skin Research Institute of Singapore (SRIS), 11 Mandalay Road #17-01 Clinical Sciences Building, Singapore 308232, Singapore"},{"name":"Program in Cancer and Stem Cell Biology, Duke-NUS Medical School 8 College Road, Singapore 169857, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/bjd.12230","article-title":"Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort","volume":"168","author":"Danielsen","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cytogfr.2010.10.007","article-title":"Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease","volume":"21","author":"Ouyang","year":"2010","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2133.2005.06909.x","article-title":"Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis","volume":"154","author":"Sampogna","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Damiani, G., Bragazzi, N.L., Karimkhani Aksut, C., Wu, D., Alicandro, G., McGonagle, D., Guo, C., Dellavalle, R., Grada, A., and Wong, P. (2021). The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front. Med., 8.","DOI":"10.3389\/fmed.2021.743180"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00510050","article-title":"Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies","volume":"275","author":"Bos","year":"1983","journal-title":"Arch. Dermatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF00424268","article-title":"Predominance of \u201cmemory\u201d T cells (CD4+, CDw29+) over \u201cna\u00efve\u201d T cells (CD4+, CD45R+) in both normal and diseased human skin","volume":"281","author":"Bos","year":"1989","journal-title":"Arch. Dermatol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/1523-1747.ep12465237","article-title":"Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells","volume":"96","author":"Morganroth","year":"1991","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.1984.tb04678.x","article-title":"Epidermal T lymphocytes and HLA-DR expression in psoriasis","volume":"110","author":"Baker","year":"1984","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1084\/jem.164.4.1013","article-title":"Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques","volume":"164","author":"Gottlieb","year":"1986","journal-title":"J. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/jaut.1999.0343","article-title":"CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry","volume":"14","author":"Ferenczi","year":"2000","journal-title":"J. Autoimmun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12499782","article-title":"Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation","volume":"98","author":"Gottlieb","year":"1992","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1615\/CritRevImmunol.v17.i2.30","article-title":"Lymphocyte activation in health and disease","volume":"17","author":"Berridge","year":"1997","journal-title":"Crit. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4049\/jimmunol.135.3.1624","article-title":"T cell activation via CD2 [T, gp50] molecules: Accessory cells are required to trigger T cell activation via CD2-D66 plus CD2-9.6\/T11(1) epitopes","volume":"135","author":"Brottier","year":"1985","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.140.5.1401","article-title":"Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA\u22123, CD2, and LFA\u22121) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production","volume":"140","author":"Sanders","year":"1988","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0065-230X(08)60477-7","article-title":"T cell receptors: Adhesion and signaling","volume":"56","author":"Bierer","year":"1991","journal-title":"Adv. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.iy.09.040191.000331","article-title":"Role of lymphocyte adhesion receptors in transient interactions and cell locomotion","volume":"9","author":"Dustin","year":"1991","journal-title":"Annu. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.147.8.2461","article-title":"CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells","volume":"147","author":"Jenkins","year":"1991","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archderm.135.9.1104","article-title":"The immunologic and genetic basis of psoriasis","volume":"135","author":"Nickoloff","year":"1999","journal-title":"Arch. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4049\/jimmunol.150.3.1105","article-title":"Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition","volume":"150","author":"Picker","year":"1993","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/1523-1747.ep12499816","article-title":"Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin","volume":"98","author":"Groves","year":"1992","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/BF00402220","article-title":"Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin","volume":"286","author":"Wakelkamp","year":"1994","journal-title":"Arch. Dermatol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s004030050299","article-title":"An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis","volume":"290","author":"Terajima","year":"1998","journal-title":"Arch. Dermatol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12371679","article-title":"The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response","volume":"101","author":"Uyemura","year":"1993","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-4362.1999.00622.x","article-title":"Cytokines in psoriasis","volume":"38","author":"Bonifati","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.26444\/aaem\/112107","article-title":"Environmental risk factors and epigenetic alternations in psoriasis","volume":"27","author":"Roszkiewicz","year":"2020","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_31","unstructured":"Nair, P.A., and Badri, T. (2024). Psoriasis. StatPearls, Treasure Island."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00002512-199812030-00002","article-title":"Recognition and treatment of psoriasis. Special considerations in elderly patients","volume":"12","author":"Bonifati","year":"1998","journal-title":"Drugs Aging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/PTT.S328572","article-title":"Comorbidity in Adult Psoriasis: Considerations for the Clinician","volume":"12","author":"Daugaard","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13555-022-00832-9","article-title":"Economic Burden of Comorbidities in Patients with Psoriasis in the USA","volume":"13","author":"Wu","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","unstructured":"Farzam, K., and Jan, A. (2024). Beta Blockers. StatPearls, Treasure Island."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1113\/jphysiol.2003.049890","article-title":"Renin: Origin, secretion and synthesis","volume":"552","author":"Persson","year":"2003","journal-title":"J. Physiol."},{"key":"ref_40","first-page":"e8964","article-title":"Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level","volume":"12","author":"Awad","year":"2020","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1111\/jdv.14662","article-title":"Reply to-chronic exposure to tetracyclines and subsequent diagnosis for non-melanoma skin cancer in a large Midwestern US population","volume":"32","author":"Vakharia","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1097\/MJT.0000000000000569","article-title":"Bullous Reactions Associated With COX\u22122 Inhibitors","volume":"24","author":"Tatu","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199503023320907","article-title":"Treatment of psoriasis","volume":"332","author":"Greaves","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Workshop of the Research Unit of the Royal College of Physicians of London, Department Of Dermatology, University of Glasgow, and British Association of Dermatologists (1991). Guidelines for management of patients with psoriasis. BMJ, 303, 829\u2013835.","DOI":"10.1136\/bmj.303.6806.829"},{"key":"ref_45","first-page":"306","article-title":"Effectiveness of topical therapy for psoriasis: Results of a national survey","volume":"55","author":"Liem","year":"1995","journal-title":"Cutis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.molcel.2004.05.027","article-title":"Computational identification of plant microRNAs and their targets, including a stress-induced miRNA","volume":"14","author":"Bartel","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1261\/rna.2183803","article-title":"A uniform system for microRNA annotation","volume":"9","author":"Ambros","year":"2003","journal-title":"RNA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/exd.14871","article-title":"The role of microRNA in psoriasis: A review","volume":"32","author":"Jiang","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jdermsci.2020.03.006","article-title":"High-throughput transcriptome and pathogenesis analysis of clinical psoriasis","volume":"98","author":"Yu","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jaci.2020.12.657","article-title":"Cross-talk between IFN-gamma and TWEAK through miR-149 amplifies skin inflammation in psoriasis","volume":"147","author":"Srivastava","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.1202695","article-title":"MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine\/threonine kinase 40","volume":"190","author":"Xu","year":"2013","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/jid.2009.294","article-title":"Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes","volume":"130","author":"Sonkoly","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjd.17256","article-title":"Downregulation of miR-145-5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis","volume":"180","author":"Yan","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e133721","DOI":"10.1172\/jci.insight.133721","article-title":"MicroRNA-148a facilitates inflammatory dendritic cell differentiation and autoimmunity by targeting MAFB","volume":"5","author":"Meng","year":"2020","journal-title":"JCI Insight"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imlet.2015.05.014","article-title":"MicroRNA-138 regulates the balance of Th1\/Th2 via targeting RUNX3 in psoriasis","volume":"166","author":"Fu","year":"2015","journal-title":"Immunol. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","article-title":"MicroRNA genes are transcribed by RNA polymerase II","volume":"23","author":"Lee","year":"2004","journal-title":"EMBO J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0969-2126(01)00685-2","article-title":"Crystallographic and modeling studies of RNase III suggest a mechanism for double-stranded RNA cleavage","volume":"9","author":"Blaszczyk","year":"2001","journal-title":"Structure"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gpb.2017.09.004","article-title":"The Role of Exportin-5 in MicroRNA Biogenesis and Cancer","volume":"16","author":"Wu","year":"2018","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1101\/gad.1158803","article-title":"Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs","volume":"17","author":"Yi","year":"2003","journal-title":"Genes. Dev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1261\/rna.033688.112","article-title":"A comprehensive analysis of precursor microRNA cleavage by human Dicer","volume":"18","author":"Feng","year":"2012","journal-title":"RNA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1749-6632.2012.06745.x","article-title":"MicroRNA-target interactions: New insights from genome-wide approaches","volume":"1271","author":"Lee","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cell.2007.12.024","article-title":"Getting to the root of miRNA-mediated gene silencing","volume":"132","author":"Eulalio","year":"2008","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0092-8674(03)00801-8","article-title":"Functional siRNAs and miRNAs exhibit strand bias","volume":"115","author":"Khvorova","year":"2003","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12964-023-01381-0","article-title":"Triggers for the onset and recurrence of psoriasis: A review and update","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00018-020-03726-1","article-title":"Immune responses and therapeutic options in psoriasis","volume":"78","author":"Afonina","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bros, M., Youns, M., Kollek, V., Buchmuller, D., Bollmann, F., Seo, E.J., Schupp, J., Montermann, E., Usanova, S., and Kleinert, H. (2018). Differentially Tolerized Mouse Antigen Presenting Cells Share a Common miRNA Signature Including Enhanced mmu-miR-223-3p Expression Which Is Sufficient to Imprint a Protolerogenic State. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00915"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.celrep.2015.09.073","article-title":"MicroRNA-223 Regulates the Differentiation and Function of Intestinal Dendritic Cells and Macrophages by Targeting C\/EBPbeta","volume":"13","author":"Zhou","year":"2015","journal-title":"Cell Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.7150\/ijbs.59876","article-title":"miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation","volume":"17","author":"Jiao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imm.12390","article-title":"MicroRNAs affect dendritic cell function and phenotype","volume":"144","author":"Smyth","year":"2015","journal-title":"Immunology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"35428","DOI":"10.1074\/jbc.M112.426866","article-title":"miR-125a-5p regulates differential activation of macrophages and inflammation","volume":"288","author":"Banerjee","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: From keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Xiuli, Y., and Honglin, W. (2021). miRNAs Flowing Up and Down: The Concerto of Psoriasis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.646796"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chiang, C.C., Cheng, W.J., Korinek, M., Lin, C.Y., and Hwang, T.L. (2019). Neutrophils in Psoriasis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02376"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Man, A.M., Orasan, M.S., Hoteiuc, O.A., Olanescu-Vaida-Voevod, M.C., and Mocan, T. (2023). Inflammation and Psoriasis: A Comprehensive Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216095"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1038\/ncomms8652","article-title":"NF-kappaB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis","volume":"6","author":"Yan","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature06642","article-title":"A skin microRNA promotes differentiation by repressing \u2018stemness\u2019","volume":"452","author":"Yi","year":"2008","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Sato, K., Takaishi, M., Tokuoka, S., and Sano, S. (2014). Involvement of TNF-alpha converting enzyme in the development of psoriasis-like lesions in a mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112408"},{"key":"ref_83","first-page":"225re1","article-title":"Targeting miR-21 to treat psoriasis","volume":"6","author":"Jimenez","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-0625.2012.01462.x","article-title":"MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis","volume":"21","author":"Meisgen","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2010.03.004","article-title":"MicroRNAs and potential target interactions in psoriasis","volume":"58","author":"Zibert","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/exd.13520","article-title":"The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis","volume":"27","author":"Masalha","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"919","DOI":"10.15252\/emmm.201505384","article-title":"Identification of a novel PPARbeta\/delta\/miR-21-3p axis in UV-induced skin inflammation","volume":"8","author":"Degueurce","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.xjidi.2022.100175","article-title":"Targeting TGF-beta1\/miR-21 Pathway in Keratinocytes Reveals Protective Effects of Silymarin on Imiquimod-Induced Psoriasis Mouse Model","volume":"3","author":"Henriet","year":"2023","journal-title":"JID Innov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/cdd.2008.69","article-title":"miR-203 represses \u2018stemness\u2019 by repressing DeltaNp63","volume":"15","author":"Lena","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/cdd.2014.113","article-title":"MicroRNAs and p63 in epithelial stemness","volume":"22","author":"Candi","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1242\/dev.089649","article-title":"Rapid and widespread suppression of self-renewal by microRNA-203 during epidermal differentiation","volume":"140","author":"Jackson","year":"2013","journal-title":"Development"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sonkoly, E., Wei, T., Janson, P.C., Saaf, A., Lundeberg, L., Tengvall-Linder, M., Norstedt, G., Alenius, H., Homey, B., and Scheynius, A. (2007). MicroRNAs: Novel regulators involved in the pathogenesis of psoriasis?. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000610"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Lammerhirt, L., Kappelmann-Fenzl, M., Fischer, S., Meier, P., Staebler, S., Kuphal, S., and Bosserhoff, A.K. (2024). Loss of miR-101-3p in melanoma stabilizes genomic integrity, leading to cell death prevention. Cell Mol. Biol. Lett., 29.","DOI":"10.1186\/s11658-024-00552-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jid.2023.07.013","article-title":"IL-17-Mediated Downregulation of miR-101 Facilitates the Expression of EZH2 to Promote Epidermal Hyperplasia in Psoriasis","volume":"144","author":"Quah","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/s41467-018-05078-8","article-title":"p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis","volume":"9","author":"Anwar","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1038\/s41467-021-26993-3","article-title":"Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein","volume":"12","author":"Tripathi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.7150\/jca.33117","article-title":"MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Beer, L., Kalinina, P., Kocher, M., Laggner, M., Jeitler, M., Abbas Zadeh, S., Copic, D., Tschachler, E., and Mildner, M. (2020). miR-155 Contributes to Normal Keratinocyte Differentiation and Is Upregulated in the Epidermis of Psoriatic Skin Lesions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239288"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopha.2017.03.105","article-title":"MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis","volume":"90","author":"Xu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jdv.13861","article-title":"Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity","volume":"31","author":"Navarro","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2058738420933742","DOI":"10.1177\/2058738420933742","article-title":"Upregulation of the miRNA-155, miRNA-210, and miRNA-20b in psoriasis patients and their relation to IL-17","volume":"34","author":"Amin","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3892\/ijmm.2024.5415","article-title":"miR-155 promotes an inflammatory response in HaCaT cells via the IRF2BP2\/KLF2\/NF-kappaB pathway in psoriasis","volume":"54","author":"Chen","year":"2024","journal-title":"Int. J. Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40291-021-00531-9","article-title":"Serum Levels of miR-146a in Patients with Psoriasis","volume":"25","author":"Leal","year":"2021","journal-title":"Mol. Diagn. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jaci.2016.07.025","article-title":"MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis","volume":"139","author":"Srivastava","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40291-024-00714-0","article-title":"MicroRNA-146a Signature in Psoriasis: A Systematic Review and Meta-Analysis","volume":"28","author":"Ho","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Mostafa, S.A., Mohammad, M.H.S., Negm, W.A., Batiha, G.E.S., Alotaibi, S.S., Albogami, S.M., Waard, M., Tawfik, N.Z., and Abdallah, H.Y. (2022). Circulating microRNA203 and its target genes\u2019 role in psoriasis pathogenesis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.988962"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1080\/15384101.2020.1783934","article-title":"miR-203 promotes HaCaT cell overproliferation through targeting LXR-alpha and PPAR-gamma","volume":"19","author":"Xiao","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.3892\/mmr.2017.7759","article-title":"miR-203 contributes to IL-17-induced VEGF secretion by targeting SOCS3 in keratinocytes","volume":"16","author":"Xu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/jid.2011.55","article-title":"MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2","volume":"131","author":"Xu","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.2147\/IJN.S441353","article-title":"Topical Delivery of microRNA-125b by Framework Nucleic Acids for Psoriasis Treatment","volume":"19","author":"Han","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lerman, G., Avivi, C., Mardoukh, C., Barzilai, A., Tessone, A., Gradus, B., Pavlotsky, F., Barshack, I., Polak-Charcon, S., and Orenstein, A. (2011). MiRNA expression in psoriatic skin: Reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020916"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jep.2016.08.028","article-title":"MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine","volume":"194","author":"Yang","year":"2016","journal-title":"J. Ethnopharmacol."},{"key":"ref_113","first-page":"461","article-title":"MiR-99a inhibits keratinocyte proliferation by targeting Frizzled-5 (FZD5) \/ FZD8 through beta-catenin signaling in psoriasis","volume":"72","author":"Shen","year":"2017","journal-title":"Pharmazie"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2018.05.040","article-title":"Ultrasound targeting of Q-starch\/miR-197 complexes for topical treatment of psoriasis","volume":"284","author":"Lerman","year":"2018","journal-title":"J. Control Release"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/exd.14169","article-title":"IL6R is a target of miR-197 in human keratinocytes","volume":"30","author":"Masalha","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_116","first-page":"6207","article-title":"MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B","volume":"14","author":"Wang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e15674","DOI":"10.15252\/emmm.202215674","article-title":"Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis","volume":"15","author":"Wang","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Reda El Sayed, S., Cristante, J., Guyon, L., Denis, J., Chabre, O., and Cherradi, N. (2021). MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers, 13.","DOI":"10.3390\/cancers13112680"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd4140","article-title":"MicroRNAs and other non-coding RNAs as targets for anticancer drug development","volume":"12","author":"Ling","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","article-title":"microRNA Therapeutics in Cancer\u2014An Emerging Concept","volume":"12","author":"Shah","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Hanna, J., Hossain, G.S., and Kocerha, J. (2019). The Potential for microRNA Therapeutics and Clinical Research. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00478"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/bjc.2013.192","article-title":"Circulating microRNAs as potential new biomarkers for prostate cancer","volume":"108","author":"Dart","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/exd.13249","article-title":"Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers","volume":"26","author":"Liu","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdermsci.2014.05.005","article-title":"MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis","volume":"75","author":"Lovendorf","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"ref_127","first-page":"S24","article-title":"Special Considerations in the Diagnosis and Treatment of Psoriasis","volume":"14","author":"Sangha","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/1346-8138.12460","article-title":"miR-424 levels in hair shaft are increased in psoriatic patients","volume":"41","author":"Tsuru","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/1346-8138.15370","article-title":"miR-205-5p inhibits psoriasis-associated proliferation and angiogenesis: Wnt\/beta-catenin and mitogen-activated protein kinase signaling pathway are involved","volume":"47","author":"Xue","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.25122\/jml-2024-0264","article-title":"Is Mir-205 a possible biomarker for evaluating treatment response in psoriasis?","volume":"17","author":"Mihu","year":"2024","journal-title":"J. Med. Life"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12935-020-01394-6","article-title":"Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies","volume":"20","author":"Javanmard","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Xu, B., Jia, H.-Y., Zhang, K., Lu, W.-J., Xu, G.-W., Zhang, J.-F., and Tang, Z.-L. (2020). LncRNA MEG3 Influences the Proliferation and Apoptosis of Psoriasis Epidermal Cells by Targeting miR-21\/Caspase-8. BMC Mol. Cell Biol., 20.","DOI":"10.1186\/s12860-019-0229-9"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","article-title":"The promise of microRNA replacement therapy","volume":"70","author":"Bader","year":"2010","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"20406223211037846","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Schakel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1105\/tpc.110.082784","article-title":"Evolution and functional diversification of MIRNA genes","volume":"23","author":"Cuperus","year":"2011","journal-title":"Plant Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2013.10.009","article-title":"Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris","volume":"150","author":"Zhao","year":"2014","journal-title":"Clin. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1172\/JCI97426","article-title":"MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation","volume":"128","author":"Wu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1073\/pnas.1200010109","article-title":"Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA","volume":"109","author":"Volinia","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000101316","article-title":"Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity","volume":"185","author":"Zavadil","year":"2007","journal-title":"Cells Tissues Organs"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1074\/jbc.M110.170852","article-title":"MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1)","volume":"286","author":"Tsuchiya","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molcel.2009.09.006","article-title":"Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation","volume":"35","author":"Huang","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_147","first-page":"6511","article-title":"MiRNA-210: A Current Overview","volume":"37","author":"Bavelloni","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_148","unstructured":"Saleh, D., and Tanner, L.S. (2024). Guttate Psoriasis. StatPearls, Treasure Island."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CCID.S189000","article-title":"Inverse Psoriasis: From Diagnosis to Current Treatment Options","volume":"12","author":"Micali","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/PTT.S101232","article-title":"Erythrodermic psoriasis: Pathophysiology and current treatment perspectives","volume":"6","author":"Singh","year":"2016","journal-title":"Psoriasis Targets Ther."},{"key":"ref_151","unstructured":"Shah, M., Al Aboud, D.M., Crane, J.S., and Kumar, S. (2024). Pustular Psoriasis. StatPearls, Treasure Island."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0190-9622(86)70201-6","article-title":"Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris","volume":"15","author":"Bernstein","year":"1986","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0190-9622(92)70060-S","article-title":"Effects of petrolatum on stratum corneum structure and function","volume":"26","author":"Ghadially","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0733-8635(18)30044-5","article-title":"Topical corticosteroids","volume":"13","author":"Katz","year":"1995","journal-title":"Dermatol. Clin."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1468-3083.2012.04522.x","article-title":"Topical corticosteroids in plaque psoriasis: A systematic review of efficacy and treatment modalities","volume":"26","author":"Castela","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_156","unstructured":"Gabros, S., Nessel, T.A., and Zito, P.M. (2024). Topical Corticosteroids. StatPearls, Treasure Island."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2133.1970.tb02214.x","article-title":"The external treatment of psoriasis. A controlled investigation of the effects of coal tar","volume":"82","author":"Young","year":"1970","journal-title":"Br. J. Dermatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archderm.1968.01610140076019","article-title":"The Goeckerman treatment of psoriasis","volume":"98","author":"Perry","year":"1968","journal-title":"Arch. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.1981.01650080019020","article-title":"Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study","volume":"117","author":"Pittelkow","year":"1981","journal-title":"Arch. Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0733-8635(18)30045-7","article-title":"Tars and anthralins","volume":"13","author":"Silverman","year":"1995","journal-title":"Dermatol. Clin."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/bmj.2.4836.591","article-title":"The approach to psoriasis","volume":"2","author":"Ingram","year":"1953","journal-title":"Br. Med. J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(84)91559-9","article-title":"Inhibition of dithranol inflammation by free-radical scavengers","volume":"2","author":"Finnen","year":"1984","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2133.1986.tb06236.x","article-title":"An open study of vitamin D3 treatment in psoriasis vulgaris","volume":"115","author":"Morimoto","year":"1986","journal-title":"Br. J. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/archderm.1989.01670240047011","article-title":"Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903)","volume":"125","author":"Kragballe","year":"1989","journal-title":"Arch. Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0140-6736(91)92157-W","article-title":"Double-blind, right\/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris","volume":"337","author":"Kragballe","year":"1991","journal-title":"Lancet"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0733-8635(18)30046-9","article-title":"Vitamin D3 analogues","volume":"13","author":"Kragballe","year":"1995","journal-title":"Dermatol. Clin."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(80)91231-3","article-title":"Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation","volume":"1","author":"Stern","year":"1980","journal-title":"Lancet"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/1523-1747.ep12496022","article-title":"Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial","volume":"68","author":"Melski","year":"1977","journal-title":"J. Investig. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/1523-1747.ep12542071","article-title":"Systemic suppression of contact hypersensitivity in mice by psoralen plus UVA radiation (PUVA)","volume":"81","author":"Kripke","year":"1983","journal-title":"J. Investig. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/jnci\/90.17.1278","article-title":"Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study","volume":"90","author":"Stern","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM198405033101805","article-title":"Cutaneous squamous-cell carcinoma in patients treated with PUVA","volume":"310","author":"Stern","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/1523-1747.ep12464137","article-title":"Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment","volume":"91","author":"Stern","year":"1988","journal-title":"J. Investig. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1111\/1523-1747.ep12505777","article-title":"Cytotoxic and immunologic effects of methotrexate in psoriasis","volume":"95","author":"Weinstein","year":"1990","journal-title":"J. Investig. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/1523-1747.ep12283594","article-title":"Cell kinetic basis for pathophysiology of psoriasis","volume":"85","author":"Weinstein","year":"1985","journal-title":"J. Investig. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.1971.04000130035004","article-title":"Methotrexate for psoriasis. A new therapeutic schedule","volume":"103","author":"Weinstein","year":"1971","journal-title":"Arch. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/archderm.1987.01660340065021","article-title":"The treatment of severe psoriasis. A national survey","volume":"123","author":"Peckham","year":"1987","journal-title":"Arch. Dermatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: Revised guidelines","volume":"19","author":"Roenigk","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0167-5699(93)90061-O","article-title":"The mechanisms of action of cyclosporin A in the treatment of psoriasis","volume":"14","author":"Wong","year":"1993","journal-title":"Immunol. Today"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/357692a0","article-title":"FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin","volume":"357","author":"Tamura","year":"1992","journal-title":"Nature"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archinte.1991.00400020106021","article-title":"Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders","volume":"151","author":"Gupta","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2133.1992.tb14848.x","article-title":"Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy","volume":"127","author":"Korstanje","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2133.1992.tb00112.x","article-title":"Consensus conference on cyclosporin A for psoriasis February 1992","volume":"126","author":"Mihatsch","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000248850","article-title":"Clinical pharmacology of 3 generations of retinoids","volume":"175","author":"Vahlquist","year":"1987","journal-title":"Dermatologica"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0190-9622(87)70264-3","article-title":"Etretinate therapy reduces inpatient treatment of psoriasis","volume":"17","author":"Ellis","year":"1987","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study","volume":"19","author":"Gollnick","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archderm.1985.01660100077019","article-title":"Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis","volume":"121","author":"Moy","year":"1985","journal-title":"Arch. Dermatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2133.1976.tb15541.x","article-title":"Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis","volume":"95","author":"Orfanos","year":"1976","journal-title":"Br. J. Dermatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/1523-1747.ep12541294","article-title":"Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative","volume":"70","author":"Fritsch","year":"1978","journal-title":"J. Investig. Dermatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2133.1984.tb07470.x","article-title":"A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis","volume":"110","author":"Parker","year":"1984","journal-title":"Br. J. Dermatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000248567","article-title":"Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis","volume":"177","author":"Saurat","year":"1988","journal-title":"Dermatologica"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/1523-1747.ep12472293","article-title":"Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol","volume":"100","author":"Larsen","year":"1993","journal-title":"J. Investig. Dermatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJM198611063151901","article-title":"Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate","volume":"315","author":"DiGiovanna","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_194","first-page":"77","article-title":"Etanercept in the treatment of plaque psoriasis","volume":"2","author":"Nguyen","year":"2009","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/TCRM.S3094","article-title":"Treatment of severe psoriasis with infliximab","volume":"4","author":"Leman","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/TCRM.S1265","article-title":"Treating psoriasis with adalimumab","volume":"4","author":"Alwawi","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/PTT.S146004","article-title":"Secukinumab in the treatment of psoriasis: Patient selection and perspectives","volume":"8","author":"Yang","year":"2018","journal-title":"Psoriasis Targets Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/1744666X.2019.1559730","article-title":"Ixekizumab for the treatment of psoriasis: An update on new data since first approval","volume":"15","author":"Blegvad","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Galluzzo, M., Tofani, L., Lombardo, P., Petruzzellis, A., Silvaggio, D., Egan, C.G., Bianchi, L., and Talamonti, M. (2020). Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072170"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (>\/=6 to < 12 years of age): Efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14712598.2017.1304537","article-title":"Tildrakizumab for treating psoriasis","volume":"17","author":"Galluzzo","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Emmanuel, T., Lybaek, D., Johansen, C., and Iversen, L. (2020). Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00083"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaad.2004.11.019","article-title":"Actinic damage among patients with psoriasis treated by climatotherapy at the Dead Sea","volume":"52","author":"David","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1046\/j.1365-2133.1999.03161.x","article-title":"Malignant tumours and psoriasis: Climatotherapy at the Dead Sea","volume":"141","author":"Frentz","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1468-3083.2002.00452.x","article-title":"Alternative treatment of psoriasis with balneotherapy using Leopoldine spa water","volume":"16","author":"Menchini","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clindermatol.2018.03.010","article-title":"The use of balneotherapy in dermatology","volume":"36","author":"Huang","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2010.02.039","article-title":"A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis","volume":"63","author":"Rook","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Ehst, B.D., Strober, B., Blauvelt, A., Maslin, D., Macaro, D., Carpenter, N., Bodmer, M., and McHale, D. (2024). A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1292406"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Bodmer, M., Itano, A., and McInnes, I. (2022). Harnessing the small intestinal axis to resolve systemic inflammation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1060607"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Itano, A., Maslin, D., Ramani, K., Mehraei, G., Carpenter, N., Cormack, T., Saghari, M., Moerland, M., Troy, E., and Caffry, W. (2023). Clinical translation of anti-inflammatory effects of Prevotella histicola in Th1, Th2, and Th17 inflammation. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1070433"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of Roflumilast Cream for Chronic Plaque Psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_213","first-page":"835","article-title":"Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis","volume":"17","author":"Pincelli","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Li, H., Zuo, J., and Tang, W. (2018). Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01048"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/bjd\/ljad315","article-title":"Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis","volume":"190","author":"Jiang","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijbiomac.2022.01.119","article-title":"Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases","volume":"202","author":"Xu","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13555-023-00939-7","article-title":"Safety and Efficacy of a Novel Combination Cream (GN-037) in Healthy Volunteers and Patients with Plaque Psoriasis: A Phase 1 Trial","volume":"13","author":"Sezer","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"107008","DOI":"10.1016\/j.intimp.2020.107008","article-title":"IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis","volume":"89","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Drakos, A., Torres, T., and Vender, R. (2024). Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010111"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Vugler, A., O\u2019Connell, J., Nguyen, M.A., Weitz, D., Leeuw, T., Hickford, E., Verbitsky, A., Ying, X., Rehberg, M., and Carrington, B. (2022). An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1037983"}],"container-title":["Non-Coding RNA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2311-553X\/11\/1\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:32:43Z","timestamp":1760027563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2311-553X\/11\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":221,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ncrna11010016"],"URL":"https:\/\/doi.org\/10.3390\/ncrna11010016","relation":{},"ISSN":["2311-553X"],"issn-type":[{"value":"2311-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}